Therapeutic Plasma Exchange and Immunoadsorption: Indications and Implementation

  • Ammon HandisuryaEmail author
  • Christof Aigner
  • Benjamin Schairer
  • Kurt Derfler
Part of the Advances and Controversies in Hematopoietic Transplantation and Cell Therapy book series (ACHTCT)


Apheresis modalities including therapeutic plasma exchange and immunoadsorption enable the rapid removal of pathogenic components from circulation via an extracorporeal circuit. After separation of plasma from corpuscular blood components, the endogenous plasma is either replaced by a substitution fluid (therapeutic plasma exchange) or loaded in reusable adsorber columns, where immunoglobulins are adsorbed (immunoadsorption). Several indications for both apheresis modalities have been established, to date, especially in the treatment of various autoantibody-mediated diseases and in the peri-transplant setting.

This chapter will provide an overview of the methodology and the potential complications of both apheresis modalities and will further focus on their implementation in the treatment of three hematological diseases, thrombotic microangiopathy, acquired coagulation inhibitors, and pure red cell aplasia after major ABO-incompatible allogenic hematopoietic stem cell transplantation.


Therapeutic plasma exchange Immunoadsorption Apheresis 


  1. Azoulay E, Knoebl P, Garnacho-Montero J, Rusinova K, Galstian G, Eggimann P, Abroug F, Benoit D, von Bergwelt-Baildon M, Wendon J, Scully M (2017) Expert statements on the standard of care in critically ill adult patients with atypical hemolytic uremic syndrome. Chest 152(2):424–434PubMedCrossRefPubMedCentralGoogle Scholar
  2. Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V, Rodriguez de Cordoba S, Pinto S, Goodship TH, Alberti M, Ribes D, Valoti E, Remuzzi G, Noris M (2013) European working party on complement genetics in renal diseases. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol 24(3):475–486PubMedPubMedCentralCrossRefGoogle Scholar
  3. Bu F, Borsa NG, Jones MB, Takanami E, Nishimura C, Hauer JJ, Azaiez H, Black-Ziegelbein EA, Meyer NC, Kolbe DL, Li Y, Frees K, Schnieders MJ, Thomas C, Nester C, Smith RJ (2016) High-throughput genetic testing for thrombotic microangiopathies and C3 glomerulopathies. J Am Soc Nephrol 27(4):1245–1253PubMedCrossRefPubMedCentralGoogle Scholar
  4. Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa M, Grinyó JM, Praga M, Torra R, Vilalta R, Rodríguez de Córdoba S (2013) An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 33(1):27–45PubMedPubMedCentralGoogle Scholar
  5. Caprioli J, Castelletti F, Bucchioni S, Bettinaglio P, Bresin E, Pianetti G, Gamba S, Brioschi S, Daina E, Remuzzi G, Noris M, International Registry of Recurrent and Familial HUS/TTP (2003) Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet 12(24):3385–3395PubMedCrossRefPubMedCentralGoogle Scholar
  6. Cheng CW, Hendrickson JE, Tormey CA, Sidhu D (2017) Therapeutic plasma exchange and its impact on drug levels: an ACLPS critical review. Am J Clin Pathol 148(3):190–198PubMedCrossRefPubMedCentralGoogle Scholar
  7. Chirnside A, Urbaniak SJ, Prowse CV, Keller AJ (1981) Coagulation abnormalities following intensive plasma exchange on the cell separator. II. Effects on factors I, II, V, VII, VIII, IX, X and antithrombin III. Br J Haematol 48(4):627–634PubMedCrossRefPubMedCentralGoogle Scholar
  8. Clark WF, Huang SS, Walsh MW, Farah M, Hildebrand AM, Sontrop JM (2016) Plasmapheresis for the treatment of kidney diseases. Kidney Int 90(5):974–984CrossRefGoogle Scholar
  9. Cornec-Le Gall E, Delmas Y, De Parscau L, Doucet L, Ogier H, Benoist JF, Fremeaux-Bacchi V, Le Meur Y (2014) Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency. Am J Kidney Dis 63(1):119–123PubMedCrossRefGoogle Scholar
  10. Cugno M, Gualtierotti R, Tedeschi A, Meroni PL (2014) Autoantibodies to coagulation factors: from pathophysiology to diagnosis and therapy. Autoimmun Rev 13(1):40–48PubMedCrossRefGoogle Scholar
  11. Dandel M, Englert A, Wallukat G, Riese A, Knosalla C, Stein J, Hetzer R (2015) Immunoadsorption can improve cardiac function in transplant candidates with non-ischemic dilated cardiomyopathy associated with diabetes mellitus. Atheroscler Suppl 18:124–133PubMedCrossRefGoogle Scholar
  12. Dellacasa CM, D’Ardia S, Allione B, Aydin S, Tassi V, Francisci T, Pecoraro C, Busca A (2015) Efficacy of plasmapheresis for the treatment of pure red blood cell aplasia after allogeneic stem cell transplantation. Transfusion 55(12):2979–2982PubMedCrossRefGoogle Scholar
  13. Delvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, Del-Favero J, Plaisance S, Claes B, Lambrechts D, Zoja C, Remuzzi G, Conway EM (2009) Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 361(4):345–357PubMedPubMedCentralCrossRefGoogle Scholar
  14. Franchini M, Mannucci PM (2013) Acquired haemophilia A: a 2013 update. Thromb Haemost 110(6):1114–1120PubMedCrossRefGoogle Scholar
  15. Freedman J, Rand ML, Russell O, Davis C, Cheatley PL, Blanchette V, Garvey MB (2003) Immunoadsorption may provide a cost-effective approach to management of patients with inhibitors to FVIII. Transfusion 43(11):1508–1513PubMedCrossRefGoogle Scholar
  16. Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaimé F, Dragon-Durey MA, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, Burtey S, Niaudet P, Deschênes G, Lebranchu Y, Zuber J, Loirat C (2013) Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 8(4):554–562PubMedPubMedCentralCrossRefGoogle Scholar
  17. George JN, Nester CM (2014) Syndromes of thrombotic microangiopathy. N Engl J Med 371(7):654–666CrossRefGoogle Scholar
  18. Goldmann G, Marquardt N, Horneff S, Oldenburg J, Zeitler H (2015) Treatment of minor severe acquired haemophilia. Is there a rationale for immunoadsorption? Atheroscler Suppl 18:74–79PubMedCrossRefGoogle Scholar
  19. Ibrahim RB, Liu C, Cronin SM, Murphy BC, Cha R, Swerdlow P, Edwards DJ (2007) Drug removal by plasmapheresis: an evidence-based review. Pharmacotherapy 27(11):1529–1549PubMedCrossRefPubMedCentralGoogle Scholar
  20. Jansen M, Schmaldienst S, Banyai S, Quehenberger P, Pabinger I, Derfler K, Hörl WH, Knöbl P (2001) Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb). Br J Haematol 112(1):91–97PubMedCrossRefPubMedCentralGoogle Scholar
  21. Józsi M, Licht C, Strobel S, Zipfel SL, Richter H, Heinen S, Zipfel PF, Skerka C (2008) Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 111(3):1512–1514PubMedCrossRefPubMedCentralGoogle Scholar
  22. Koefoed-Nielsen P, Bistrup C, Christiansen M (2017) Protein a immunoadsorption may hamper the decision to transplant due to interference with CDC crossmatch results. J Clin Apher 32(3):163–169PubMedCrossRefPubMedCentralGoogle Scholar
  23. Kruse-Jarres R, Kempton CL, Baudo F, Collins PW, Knoebl P, Leissinger CA, Tiede A, Kessler CM (2017) Acquired hemophilia A: updated review of evidence and treatment guidance. Am J Hematol 92(7):695–705PubMedCrossRefPubMedCentralGoogle Scholar
  24. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368(23):2169–2181PubMedCrossRefPubMedCentralGoogle Scholar
  25. Lemaire M, Frémeaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le Quintrec M, Fakhouri F, Taque S, Nobili F, Martinez F, Ji W, Overton JD, Mane SM, Nürnberg G, Altmüller J, Thiele H, Morin D, Deschenes G, Baudouin V, Llanas B, Collard L, Majid MA, Simkova E, Nürnberg P, Rioux-Leclerc N, Moeckel GW, Gubler MC, Hwa J, Loirat C, Lifton RP (2013) Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 45(5):531–536PubMedPubMedCentralCrossRefGoogle Scholar
  26. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G (2010) Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5(10):1844–1859PubMedPubMedCentralCrossRefGoogle Scholar
  27. Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knöbl P, Wu H, Artoni A, Westwood JP, Mansouri Taleghani M, Jilma B, Callewaert F, Ulrichts H, Duby C, Tersago D, Investigators TITAN (2016) Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 374(6):511–522PubMedCrossRefPubMedCentralGoogle Scholar
  28. Puisset F, White-Koning M, Kamar N, Huart A, Haberer F, Blasco H, Le Guellec C, Lafont T, Grand A, Rostaing L, Chatelut E, Pourrat J (2013) Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease. Br J Clin Pharmacol 76(5):734–740PubMedPubMedCentralCrossRefGoogle Scholar
  29. Rabitsch W, Knöbl P, Greinix H, Prinz E, Kalhs P, Hörl WH, Derfler K (2003a) Removal of persisting isohaemagglutinins with Ig-Therasorb immunoadsorption after major ABO-incompatible non-myeloablative allogeneic haematopoietic stem cell transplantation. Nephrol Dial Transplant 18(11):2405–2408PubMedCrossRefPubMedCentralGoogle Scholar
  30. Rabitsch W, Knöbl P, Prinz E, Keil F, Greinix H, Kalhs P, Worel N, Jansen M, Hörl WH, Derfler K (2003b) Prolonged red cell aplasia after major ABO-incompatible allogeneic hematopoietic stem cell transplantation: removal of persisting isohemagglutinins with Ig-Therasorb immunoadsorption. Bone Marrow Transplant 32(10):1015–1019PubMedCrossRefPubMedCentralGoogle Scholar
  31. Raval JS, Mazepa MA, Whinna HC, Park YA (2017) Monitoring therapeutic apheresis utilization: database versus registry. J Clin Apher 32(3):208–209PubMedCrossRefPubMedCentralGoogle Scholar
  32. Reese JA, Bougie DW, Curtis BR, Terrell DR, Vesely SK, Aster RH, George JN (2015) Drug-induced thrombotic microangiopathy: experience of the Oklahoma registry and the BloodCenter of Wisconsin. Am J Hematol 90(5):406–410PubMedPubMedCentralCrossRefGoogle Scholar
  33. Rock G; Members of the Canadian Apheresis Group (2017) The Canadian apheresis group registry. Transfus Apher Sci 56(1):86–88CrossRefGoogle Scholar
  34. Sana G, Dragon-Durey MA, Charbit M, Bouchireb K, Rousset-Rouvière C, Bérard E, Salomon R, Frémeaux-Bacchi V, Niaudet P, Boyer O (2014) Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses. Pediatr Nephrol 29(1):75–83PubMedCrossRefGoogle Scholar
  35. Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, Dunbar NM, Witt V, Wu Y, Shaz BH (2016) Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing Committee of the American Society for apheresis: the seventh special issue. J Clin Apher 31(3):149–162PubMedPubMedCentralGoogle Scholar
  36. Solomon A, Fahey JL (1963) Plasmapheresis therapy in macroglobulinemia. Ann Intern Med 58:789–800PubMedCrossRefGoogle Scholar
  37. Stummvoll GH, Schmaldienst S, Smolen JS, Derfler K, Biesenbach P (2012) Lupus nephritis: prolonged immunoadsorption (IAS) reduces proteinuria and stabilizes global disease activity. Nephrol Dial Transplant 27(2):618–626PubMedCrossRefGoogle Scholar
  38. Stummvoll G, Aringer M, Handisurya A, Derfler K (2017) Immunoadsorption in autoimmune diseases affecting the kidney. Semin Nephrol 37(5):478–487PubMedCrossRefGoogle Scholar
  39. Süfke S, Lehnert H, Uhlenbusch-Körwer I, Gebauer F (2017) Safety aspects of immunoadsorption in IgG removal using a single-use, multiple-pass protein a immunoadsorber (LIGASORB): clinical investigation in healthy volunteers. Ther Apher Dial 21(4):405–413PubMedCrossRefPubMedCentralGoogle Scholar
  40. Worel N (2016) ABO-mismatched allogeneic hematopoietic stem cell transplantation. Transfus Med Hemother 43(1):3–12PubMedCrossRefPubMedCentralGoogle Scholar
  41. Zöllner S, Pablik E, Druml W, Derfler K, Rees A, Biesenbach P (2014) Fibrinogen reduction and bleeding complications in plasma exchange, immunoadsorption and a combination of the two. Blood Purif 38(2):160–166PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Ammon Handisurya
    • 1
    • 2
    Email author
  • Christof Aigner
    • 1
  • Benjamin Schairer
    • 1
  • Kurt Derfler
    • 1
  1. 1.Apheresis Unit, Division of Nephrology and Dialysis, Department of Medicine IIIMedical University of ViennaViennaAustria
  2. 2.1st Medical DepartmentHanusch HospitalViennaAustria

Personalised recommendations